31 84

Cited 0 times in

Oxygen care and treatment of retinopathy of prematurity in ocular and neurological prognosis

 Hyun Goo Kang  ;  Eun Young Choi  ;  Hyuna Cho  ;  Min Kim  ;  Christopher Seungkyu Lee  ;  Soon Min Lee 
 SCIENTIFIC REPORTS, Vol.12(1) : 341, 2022-01 
Journal Title
Issue Date
Age Factors ; Angiogenesis Inhibitors / adverse effects ; Angiogenesis Inhibitors / therapeutic use* ; Bevacizumab / adverse effects ; Bevacizumab / therapeutic use* ; Birth Weight ; Child Development ; Child, Preschool ; Comorbidity ; Electronic Health Records ; Gestational Age ; Humans ; Infant ; Infant, Low Birth Weight ; Infant, Newborn ; Infant, Premature ; Laser Coagulation* / adverse effects ; Oxygen Inhalation Therapy* / adverse effects ; Ranibizumab / adverse effects ; Ranibizumab / therapeutic use* ; Respiration, Artificial* / adverse effects ; Retinopathy of Prematurity / diagnosis ; Retinopathy of Prematurity / etiology ; Retinopathy of Prematurity / therapy* ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
This retrospective cohort study aimed to investigate the effects of neonatal oxygen care and retinopathy of prematurity (ROP) treatment on ROP-related ocular and neurological prognoses. We included premature infants treated for ROP at a tertiary referral center between January 2006 and December 2019. Demographic and clinical data were collected from electronic medical records. Odds ratios (ORs) of oxygen care- and ROP treatment-related factors were calculated for ocular and neurological comorbidities 3 years after ROP treatment, after adjusting for potential confounders. ROP requiring treatment was detected in 171 eyes (88 infants). Laser treatment for ROP (OR = 4.73, 95% confidence interval [CI] 1.64-13.63) and duration of invasive ventilation (OR = 1.02, 95% CI 1.00-1.03) were associated with an increase in ocular comorbidities, along with a history of neonatal seizure (OR = 28.29, 95% CI 5.80-137.95) and chorioamnionitis (OR = 32.13, 95% CI 5.47-188.74). No oxygen care- or ROP treatment-related factors showed significant odds for neurological comorbidities. Shorter duration of invasive oxygen supply during neonatal care (less than 49 days) and anti-vascular endothelial growth factor injection as the primary treatment for ROP are less likely to cause ocular comorbidities. No association was identified between ROP treatment modalities and the risk of neurological comorbidities.
Files in This Item:
T202200206.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Hyun Goo(강현구) ORCID logo https://orcid.org/0000-0001-8359-9618
Kim, Min(김민) ORCID logo https://orcid.org/0000-0003-1873-6959
Lee, Soon Min(이순민) ORCID logo https://orcid.org/0000-0003-0174-1065
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
Choi, Eun Young(최은영) ORCID logo https://orcid.org/0000-0002-1668-6452
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.